|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
CA2435503C
(en)
|
2001-01-19 |
2011-02-22 |
Ludwig Institute For Cancer Research |
Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
EP1575548B1
(en)
|
2002-05-04 |
2011-03-09 |
Acorda Therapeutics, Inc. |
Compositions and methods for promoting neuronal outgrowth
|
|
ATE354592T1
(de)
*
|
2003-03-28 |
2007-03-15 |
Regeneron Pharma |
Vegf-antagonisten zur behandlung von diabetes
|
|
AU2004247025B8
(en)
*
|
2003-05-16 |
2011-06-30 |
Acorda Therapeutics, Inc. |
Fusion proteins for the treatment of CNS
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
US7429375B2
(en)
|
2003-05-16 |
2008-09-30 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for the treatment of CNS
|
|
MXPA05008973A
(es)
*
|
2003-05-28 |
2006-02-22 |
Regeneron Pharma |
Metodo de tratamiento de rechazo de trasplante de cornea.
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
CA2519875C
(en)
*
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050112061A1
(en)
*
|
2003-08-06 |
2005-05-26 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
ES2411504T3
(es)
|
2004-05-18 |
2013-07-05 |
Acorda Therapeutics, Inc. |
Métodos de purificación de condroitinasa y formulaciones estables de la misma
|
|
PL1767546T3
(pl)
*
|
2004-06-08 |
2012-07-31 |
Chengdu Kanghong Biotechnologies Co Ltd |
Hamujące angiogenezę białka chimeryczne i ich zastosowanie
|
|
CA2567686A1
(en)
*
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
CN1968709A
(zh)
*
|
2004-06-18 |
2007-05-23 |
瑞泽恩制药公司 |
用于治疗恶性胸腔积液的vegf抑制剂
|
|
AU2005267741A1
(en)
|
2004-07-30 |
2006-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type I diabetes by blocking VEGF-mediated activity
|
|
CN101094688B
(zh)
|
2004-09-13 |
2013-05-01 |
建新公司 |
多聚构建体
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
EP1877438A2
(en)
|
2005-02-02 |
2008-01-16 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
HUE034109T2
(en)
|
2005-03-25 |
2018-01-29 |
Regeneron Pharma |
VEGF antagonist formulations
|
|
WO2007038548A2
(en)
|
2005-09-26 |
2007-04-05 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
DK1962895T3
(da)
†
|
2005-12-16 |
2013-03-04 |
Regeneron Pharma |
TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
SI2944306T1
(sl)
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
HUE028379T2
(en)
|
2006-09-29 |
2016-12-28 |
Oncomed Pharm Inc |
Preparations and procedures for the diagnosis and treatment of cancer
|
|
EP2450442B1
(en)
|
2006-10-10 |
2017-07-19 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
MX359570B
(es)
|
2008-11-03 |
2018-10-01 |
Molecular Partners Ag |
Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
|
|
CN101838329A
(zh)
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
US8883145B2
(en)
|
2009-10-16 |
2014-11-11 |
Oncomed Pharmaceuticals, Inc. |
Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
HRP20180154T1
(hr)
|
2010-08-06 |
2018-03-09 |
Genzyme Corporation |
Pripravci vegf antagonista i njihova uporaba
|
|
EP2662385A4
(en)
*
|
2011-01-07 |
2015-11-11 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
|
|
CN103533950A
(zh)
|
2011-01-13 |
2014-01-22 |
瑞泽恩制药公司 |
Vegf拮抗剂在治疗血管生成眼病中的用途
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
JP6138815B2
(ja)
|
2011-12-01 |
2017-05-31 |
エーピー バイオサイエンシーズ， インコーポレイテッド |
補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
PL2846836T3
(pl)
|
2012-05-07 |
2020-01-31 |
Allergan, Inc. |
Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
MY199344A
(en)
|
2013-02-18 |
2023-10-24 |
Vegenics Pty Ltd |
Ligand binding molecules and uses thereof
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
EP3628324A1
(en)
|
2013-11-05 |
2020-04-01 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
HUE057653T2
(hu)
|
2014-12-11 |
2022-05-28 |
Bayer Healthcare Llc |
Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
WO2017085253A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
AU2016356717B2
(en)
|
2015-11-18 |
2022-09-29 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
|
CN108697792A
(zh)
*
|
2015-11-19 |
2018-10-23 |
珠海泰瑞尚生物医药科技有限公司 |
用于结合vegf的方法和组合物
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
WO2017129685A1
(en)
|
2016-01-26 |
2017-08-03 |
Formycon Ag |
Liquid formulation of a vegf antagonist
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
CA3043487A1
(en)
|
2016-11-21 |
2018-05-24 |
Just-Evotec Biologics Inc |
Aflibercept formulations and uses thereof
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
ES2887046T3
(es)
|
2017-08-17 |
2021-12-21 |
Just Evotec Biologics Inc |
Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
|
|
WO2019099965A1
(en)
|
2017-11-20 |
2019-05-23 |
Just Biotherapeutics, Inc. |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
ES2946747T3
(es)
|
2017-11-27 |
2023-07-25 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis
|
|
AU2018375398C1
(en)
|
2017-11-30 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Use of a VEGF antagonist to treat angiogenic eye disorders
|
|
US11460452B2
(en)
*
|
2017-12-13 |
2022-10-04 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
|
EP3730126B1
(en)
|
2017-12-22 |
2025-05-14 |
Samsung Bioepis Co., Ltd. |
Liquid composition comprising vegf antagonist
|
|
US11524053B2
(en)
*
|
2018-01-26 |
2022-12-13 |
The Regents Of The University Of California |
Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
JP7235770B2
(ja)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
US20220204920A1
(en)
|
2019-05-16 |
2022-06-30 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
CA3150481A1
(en)
|
2019-09-03 |
2021-03-11 |
Amgen Inc. |
Injection device for drug delivery and packaging for the injection device
|
|
MX2022002980A
(es)
|
2019-09-16 |
2022-04-06 |
Amgen Inc |
Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
AU2020393842A1
(en)
|
2019-11-25 |
2022-06-16 |
The Regents Of The University Of California |
Long-acting VEGF inhibitors for intraocular neovascularization
|
|
KR20240007293A
(ko)
|
2019-12-06 |
2024-01-16 |
리제너론 파아마슈티컬스, 인크. |
항-vegf 단백질 조성물 및 이를 생산하는 방법
|
|
KR20220110555A
(ko)
|
2019-12-06 |
2022-08-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Vegf 미니-트랩 및 그의 사용 방법
|
|
CA3167020A1
(en)
|
2020-02-24 |
2021-09-02 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
MX2022013812A
(es)
|
2020-05-08 |
2022-12-15 |
Regeneron Pharma |
Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
|
|
WO2022231930A1
(en)
|
2021-04-26 |
2022-11-03 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023092324A1
(zh)
|
2021-11-24 |
2023-06-01 |
苏州光度生物科技有限公司 |
多特异性配体结合分子及其应用
|
|
EP4549455A1
(en)
*
|
2022-08-02 |
2025-05-07 |
Panolos Bioscience, Inc. |
Modified fusion protein and use thereof
|
|
TW202412840A
(zh)
|
2022-09-16 |
2024-04-01 |
大陸商齊魯製藥有限公司 |
一種穩定的高濃度自緩衝藥物組合物
|
|
AU2024322540A1
(en)
*
|
2023-08-04 |
2026-03-05 |
Panolos Bioscience, Inc. |
Conjugate of modified fusion protein and scfv, and use thereof
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|